Market News

Advent Capital Management Holding in Flexion Therapeutics (FLXN) Raised by $4.23 Million as Stock Declined; Facebook (FB) Holder Ashfield Capital Partners Has Lowered Its Position by $852,720 as Share Price Declined

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Logo

Ashfield Capital Partners Llc decreased its stake in Facebook Inc (FB) by 7.93% based on its latest 2017Q4 regulatory filing with the SEC. Ashfield Capital Partners Llc sold 4,845 shares as the company’s stock declined 14.10% with the market. The institutional investor held 56,253 shares of the technology company at the end of 2017Q4, valued at $9.93M, down from 61,098 at the end of the previous reported quarter. Ashfield Capital Partners Llc who had been investing in Facebook Inc for a number of months, seems to be less bullish one the $486.40 billion market cap company. The stock decreased 0.20% or $0.34 during the last trading session, reaching $167.76. About 4.71M shares traded. Facebook, Inc. (NASDAQ:FB) has risen 8.48% since April 20, 2017 and is uptrending. It has underperformed by 3.07% the S&P500.

Advent Capital Management increased its stake in Flexion Therapeutics Inc (FLXN) by 1128.45% based on its latest 2017Q4 regulatory filing with the SEC. Advent Capital Management bought 169,267 shares as the company’s stock declined 8.56% with the market. The institutional investor held 184,267 shares of the health care company at the end of 2017Q4, valued at $4.61 million, up from 15,000 at the end of the previous reported quarter. Advent Capital Management who had been investing in Flexion Therapeutics Inc for a number of months, seems to be bullish on the $925.06M market cap company. The stock decreased 1.99% or $0.5 during the last trading session, reaching $24.59. About 234,491 shares traded. Flexion Therapeutics, Inc. (NASDAQ:FLXN) has declined 21.46% since April 20, 2017 and is downtrending. It has underperformed by 33.01% the S&P500.

Investors sentiment increased to 1.21 in Q4 2017. Its up 0.06, from 1.15 in 2017Q3. It increased, as 57 investors sold FB shares while 621 reduced holdings. 147 funds opened positions while 670 raised stakes. 1.61 billion shares or 1.26% less from 1.63 billion shares in 2017Q3 were reported. Hartline Investment Corporation accumulated 33,702 shares. Premier Asset Lc reported 2.78% of its portfolio in Facebook, Inc. (NASDAQ:FB). Impala Asset Management Ltd Com stated it has 0.33% of its portfolio in Facebook, Inc. (NASDAQ:FB). Hillman accumulated 231,615 shares or 10.82% of the stock. One National Association holds 1.36% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 113,808 shares. Fin holds 0.09% or 1,380 shares. Bancshares Of Montreal Can accumulated 2.35M shares or 0.36% of the stock. Aviance Management Lc stated it has 0.01% in Facebook, Inc. (NASDAQ:FB). Pinnacle Associate Limited stated it has 78,191 shares. Ct Mason invested 2.6% in Facebook, Inc. (NASDAQ:FB). Northrock Prns Limited Liability Company has invested 0.09% in Facebook, Inc. (NASDAQ:FB). Seabridge Inv Ltd Co has 0.07% invested in Facebook, Inc. (NASDAQ:FB) for 1,713 shares. Alkeon Capital Limited Com invested in 1.5% or 1.45M shares. Thompson Davis & Communications stated it has 4,840 shares or 2.02% of all its holdings. Teacher Retirement Of Texas owns 1.42 million shares.

Among 55 analysts covering Facebook (NASDAQ:FB), 50 have Buy rating, 2 Sell and 3 Hold. Therefore 91% are positive. Facebook had 253 analyst reports since July 21, 2015 according to SRatingsIntel. As per Thursday, November 3, the company rating was maintained by Jefferies. Mizuho maintained Facebook, Inc. (NASDAQ:FB) rating on Thursday, February 1. Mizuho has “Buy” rating and $250.0 target. As per Tuesday, September 26, the company rating was maintained by FBN Securities. On Monday, September 11 the stock rating was maintained by BMO Capital Markets with “Hold”. As per Friday, July 21, the company rating was maintained by Deutsche Bank. The firm has “Buy” rating by Argus Research given on Friday, November 6. BMO Capital Markets maintained Facebook, Inc. (NASDAQ:FB) rating on Thursday, November 3. BMO Capital Markets has “Market Perform” rating and $125 target. On Thursday, November 30 the stock rating was maintained by Robert W. Baird with “Buy”. As per Thursday, November 5, the company rating was maintained by Monness Crespi & Hardt. Mizuho maintained the stock with “Buy” rating in Thursday, July 30 report.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on April, 25 after the close. They expect $1.36 earnings per share, up 30.77% or $0.32 from last year’s $1.04 per share. FB’s profit will be $3.94 billion for 30.84 P/E if the $1.36 EPS becomes a reality. After $2.20 actual earnings per share reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts -38.18% negative EPS growth.

Since October 17, 2017, it had 0 insider purchases, and 41 selling transactions for $1.29 billion activity. 16,000 Facebook, Inc. (NASDAQ:FB) shares with value of $2.80M were sold by Cox Christopher K. Shares for $221.33M were sold by Koum Jan. The insider Sandberg Sheryl sold 55,000 shares worth $8.57 million. $2.66M worth of stock was sold by Wehner David M. on Thursday, February 22. Shares for $134,125 were sold by Stretch Colin. Schroepfer Michael Todd also sold $6.94M worth of Facebook, Inc. (NASDAQ:FB) on Tuesday, March 13.

Ashfield Capital Partners Llc, which manages about $2.94B and $777.43M US Long portfolio, upped its stake in Alibaba Group Hldg Ltd (NYSE:BABA) by 2,201 shares to 20,369 shares, valued at $3.51M in 2017Q4, according to the filing. It also increased its holding in Vanguard Index Fds (VNQ) by 4,165 shares in the quarter, for a total of 20,653 shares, and has risen its stake in Chevron Corp New (NYSE:CVX).

Advent Capital Management, which manages about $5.22B US Long portfolio, decreased its stake in Salesforce.Com Inc (Prn) by 2.52M shares to 11.15 million shares, valued at $17.10M in 2017Q4, according to the filing. It also reduced its holding in Cemex Sab De Cv (Prn) by 10.61 million shares in the quarter, leaving it with 18.02 million shares, and cut its stake in Tesla Inc (Prn).

Flexion Therapeutics, Inc. (NASDAQ:FLXN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *